vs
REPLIGEN CORP（RGEN）与WSFS FINANCIAL CORP（WSFS）财务数据对比。点击上方公司名可切换其他公司
WSFS FINANCIAL CORP的季度营收约是REPLIGEN CORP的1.4倍（$275.3M vs $194.3M），WSFS FINANCIAL CORP净利率更高（31.5% vs 4.3%，领先27.2%），REPLIGEN CORP同比增速更快（14.8% vs 7.5%），过去两年REPLIGEN CORP的营收复合增速更高（12.3% vs 1.7%）
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
WSFS金融集团是一家金融服务企业，核心子公司WSFS银行是总部位于特拉华州及大特拉华谷地区规模最大、经营历史最久的本地管理银行与财富管理机构。集团共运营115个网点，其中88个为银行网点，分布在宾夕法尼亚、特拉华、新泽西、佛罗里达、弗吉尼亚、内华达六州，提供全面金融服务。
RGEN vs WSFS — 直观对比
营收规模更大
WSFS
是对方的1.4倍
$194.3M
营收增速更快
RGEN
高出7.3%
7.5%
净利率更高
WSFS
高出27.2%
4.3%
两年增速更快
RGEN
近两年复合增速
1.7%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $194.3M | $275.3M |
| 净利润 | $8.3M | $86.8M |
| 毛利率 | 55.7% | — |
| 营业利润率 | 8.2% | — |
| 净利率 | 4.3% | 31.5% |
| 营收同比 | 14.8% | 7.5% |
| 净利润同比 | 42.9% | 31.7% |
| 每股收益（稀释后） | $0.15 | $1.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RGENWSFS
| Q1 26 | $194.3M | $275.3M | ||
| Q4 25 | $197.9M | $271.9M | ||
| Q3 25 | $188.8M | $270.5M | ||
| Q2 25 | $182.4M | $267.5M | ||
| Q1 25 | $169.2M | $256.1M | ||
| Q4 24 | $174.1M | $261.5M | ||
| Q3 24 | $154.9M | $267.7M | ||
| Q2 24 | $154.1M | $266.0M |
净利润RGENWSFS
| Q1 26 | $8.3M | $86.8M | ||
| Q4 25 | $13.3M | $72.7M | ||
| Q3 25 | $14.9M | $76.4M | ||
| Q2 25 | $14.9M | $72.3M | ||
| Q1 25 | $5.8M | $65.9M | ||
| Q4 24 | $-30.3M | $64.2M | ||
| Q3 24 | $-654.0K | $64.4M | ||
| Q2 24 | $3.3M | $69.3M |
毛利率RGENWSFS
| Q1 26 | 55.7% | — | ||
| Q4 25 | 52.5% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 50.0% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 26.1% | — | ||
| Q3 24 | 50.0% | — | ||
| Q2 24 | 49.8% | — |
营业利润率RGENWSFS
| Q1 26 | 8.2% | — | ||
| Q4 25 | 9.0% | 35.8% | ||
| Q3 25 | 8.9% | 37.3% | ||
| Q2 25 | 7.6% | 35.7% | ||
| Q1 25 | 3.9% | 34.0% | ||
| Q4 24 | -17.7% | 32.3% | ||
| Q3 24 | -5.1% | 31.9% | ||
| Q2 24 | 1.0% | 34.0% |
净利率RGENWSFS
| Q1 26 | 4.3% | 31.5% | ||
| Q4 25 | 6.7% | 26.7% | ||
| Q3 25 | 7.9% | 28.3% | ||
| Q2 25 | 8.2% | 27.0% | ||
| Q1 25 | 3.4% | 25.7% | ||
| Q4 24 | -17.4% | 24.6% | ||
| Q3 24 | -0.4% | 24.1% | ||
| Q2 24 | 2.2% | 26.0% |
每股收益（稀释后）RGENWSFS
| Q1 26 | $0.15 | $1.64 | ||
| Q4 25 | $0.24 | $1.33 | ||
| Q3 25 | $0.26 | $1.37 | ||
| Q2 25 | $0.26 | $1.27 | ||
| Q1 25 | $0.10 | $1.12 | ||
| Q4 24 | $-0.55 | $1.08 | ||
| Q3 24 | $-0.01 | $1.08 | ||
| Q2 24 | $0.06 | $1.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $582.6M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $2.7B |
| 总资产 | $2.9B | $22.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RGENWSFS
| Q1 26 | $582.6M | — | ||
| Q4 25 | $767.6M | $1.7B | ||
| Q3 25 | $748.7M | — | ||
| Q2 25 | $708.9M | — | ||
| Q1 25 | $697.2M | — | ||
| Q4 24 | $757.4M | $1.2B | ||
| Q3 24 | $784.0M | — | ||
| Q2 24 | $809.1M | — |
总债务RGENWSFS
| Q1 26 | — | — | ||
| Q4 25 | $542.2M | — | ||
| Q3 25 | $537.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $525.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益RGENWSFS
| Q1 26 | — | $2.7B | ||
| Q4 25 | $2.1B | $2.7B | ||
| Q3 25 | $2.1B | $2.8B | ||
| Q2 25 | $2.1B | $2.7B | ||
| Q1 25 | $2.0B | $2.7B | ||
| Q4 24 | $2.0B | $2.6B | ||
| Q3 24 | $2.0B | $2.7B | ||
| Q2 24 | $2.0B | $2.5B |
总资产RGENWSFS
| Q1 26 | $2.9B | $22.1B | ||
| Q4 25 | $2.9B | $21.3B | ||
| Q3 25 | $2.9B | $20.8B | ||
| Q2 25 | $2.9B | $20.8B | ||
| Q1 25 | $2.9B | $20.5B | ||
| Q4 24 | $2.8B | $20.8B | ||
| Q3 24 | $2.8B | $20.9B | ||
| Q2 24 | $2.9B | $20.7B |
负债/权益比RGENWSFS
| Q1 26 | — | — | ||
| Q4 25 | 0.26× | — | ||
| Q3 25 | 0.26× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RGEN
| Product | $194.2M | 100% |
| Royalty and other revenue | $44.0K | 0% |
WSFS
暂无分部数据
